-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下:基於2027財年(9月)8.3倍的本益比,我們將ADNT的12個月目標價下調2美元至24美元,該市盈率較ADNT的歷史市盈率存在合理的折讓。我們將2026財年的調整後每股盈餘預期從2.25美元下調至2.15美元,並將2027財年的調整後每股盈餘預期從3.10美元下調至2.90美元。鑑於ADNT的利潤超出預期並略微上調了2026財年的業績指引,我們下調了預期和目標價,並維持對該股的「持有」評級。 ADNT公佈的2026財年第二季調整後每股盈餘為0.52美元,高於市場預期的0.69美元(下降25%),遠高於市場普遍預期的0.44美元。業績超預期主要歸功於強勁的銷售成長,營收成長7%至38.7億美元(比市場預期高出2.3億美元),調整後EBITDA利潤率下降70個基點至5.8%(符合預期)。我們認為,相較於座椅業務,那些在市場高成長領域(例如自動駕駛軟體或顯示器)擁有更大份額的汽車供應商更具風險/回報潛力,並且預計未來幾個季度利潤率壓力將持續存在,尤其值得注意的是,其利潤率最高的地區(亞洲)正面臨最大的挑戰。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.